Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.

Rocco CapuanoManuela AltieriMiriana ConteAlvino BiseccoAlessandro d'AmbrosioGiovanna DonnarummaElena GrimaldiNicola CoppolaNicola MediciMassimiliano GaldieroGioacchino TedeschiAntonio Gallo

Published in: Journal of neurology (2022)

The third booster dose of BNT162b2 mRNA vaccine to OCR- and FNG-treated pwMS revives the humoral response, independently of any clinical variable, and manifests a good safety and tolerability profile.

Keyphrases

immune response
coronavirus disease
multiple sclerosis
sars cov
clinical trial
newly diagnosed